Rare condition

Chronic inflammatory demyelinating polyneuropathy

ORPHA:2932 ↗

Search all Chronic inflammatory demyelinating polyneuropathy trialsAlert me when a trial opens

studies recruiting now

as of 7 Sept 2026

145

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

20 Apr 2026

most recent study posted

among recruiting studies

Recruiting trials

RecruitingPhase 3NCT07540221

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Sponsor Grifols Therapeutics LLCWhere United States, Czechia, Poland (10 sites)Studying Gamunex-C, XembifyUpdated 4 Sept 2026

See details

RecruitingPhase 3NCT06858579

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Sponsor Dianthus TherapeuticsWhere United States, Argentina, Australia +27 (192 sites)Studying Claseprubart, ClaseprubartUpdated 2 Sept 2026

See details

RecruitingPhase 2 / Phase 3NCT05327114

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor Janssen Research & Development, LLCWhere United States, Argentina, Australia +16 (120 sites)Studying Nipocalimab, PlaceboUpdated 28 Aug 2026

See details

RecruitingPhase 3NCT06290141

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor SanofiWhere United States, Argentina, Belgium +21 (135 sites)Studying riliprubart, PlaceboUpdated 26 Aug 2026

See details

RecruitingPhase 3NCT06920004

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Sponsor argenxWhere United States, Argentina, Austria +26 (89 sites)Studying empasiprubart, IVIgUpdated 26 Aug 2026

See details

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 39 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

Keep watching

Get an email when a new Chronic inflammatory demyelinating polyneuropathy study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:2932 ↗

About Chronic inflammatory demyelinating polyneuropathy

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Orphanet expert page ↗GARD (NIH) ↗

Treatments being studied

8 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Phase 3Nipocalimab

Phase 3Riliprubart

Phase 3Rituximab (Blitzima)

Phase 3Human Immunoglobulin G (Flebogamma dif (previously flebogammadif))

Phase 2Cyclophosphamide (Cyclophosphamide)

Phase 2Batoclimab

Phase 2Corticotropin (Acth)

Phase 2Efgartigimod Alfa (Efgartigimod alfa component of vyvgart hytrulo)

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).